FDA Early Alert

Baxter Volara System Patient Circuits

FDA Issues Early Alert for Baxter Volara System Patient Circuits Following Therapy Leakage Concerns

The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Baxter Volara System patient circuits used in respiratory therapy.

According to Baxter, affected single-patient-use circuits may experience air and medication leakage from the nebulizer cup during therapy, potentially reducing the effectiveness of prescribed treatment and increasing the risk of respiratory complications.

The FDA is currently reviewing the issue and will continue providing updates as additional information becomes available.

Affected Devices

The alert applies to certain Volara System patient circuits used with the Baxter Volara respiratory therapy platform, including:

  • Volara Patient Circuit Kit HC
  • Volara Patient Circuit 5 Kit
  • Volara Patient Circuit Kit AC
  • Volara Patient Circuit 5 Kit AC

Healthcare facilities and home-care providers should review Baxter’s Urgent Medical Device Correction notice to identify affected inventory.

Potential Patient Risks

Baxter reported that leakage may occur if the nebulizer cup is damaged or not fully engaged and locked after medication is added.

When leakage occurs, patients may receive less medication than intended and experience reduced therapeutic benefit.

Potential adverse consequences include:

  • Ineffective nebulization
  • Reduced medication delivery to the lungs
  • Increased airway inflammation
  • Mucus retention
  • Mucus plugging
  • Respiratory infection
  • Prolonged coughing
  • Worsening shortness of breath
  • Reduced oxygenation

In addition, air leaks within the breathing circuit may result in lower-than-prescribed tidal volumes, potentially leading to hypoxia, hypoventilation, and respiratory compromise. The risk may be particularly significant for pediatric patients receiving therapy in the home-care setting.

As of May 21, 2026, Baxter reported one serious injury associated with the issue. No deaths have been reported.

Recommended Actions

Baxter recommends that healthcare providers, caregivers, and patients:

  • Carefully inspect the nebulizer cup before each use.
  • Ensure the nebulizer cup is filled and securely locked during assembly.
  • Discontinue use and replace the patient circuit if leakage is observed.
  • Contact a healthcare provider if leakage persists or there is uncertainty about continuing therapy.
  • Distribute the correction notice to all users and affected facilities.

Replacement patient circuits remain available through normal distribution channels.

Regulatory Perspective

The FDA’s Early Alert program is designed to rapidly communicate potentially serious device issues before the agency completes a full evaluation.

This alert highlights the importance of component-level verification and user assembly processes in respiratory therapy systems. While the reported issue appears linked to nebulizer cup engagement, the resulting therapy interruption can affect both mechanical and pharmacologic treatment outcomes.

For respiratory support devices, even seemingly minor assembly issues can result in reduced treatment effectiveness and patient harm, particularly among vulnerable patient populations.

MDP Takeaway

Healthcare organizations using Baxter Volara Systems should immediately review Baxter’s correction notice, educate respiratory therapy and clinical staff regarding proper nebulizer cup assembly, and reinforce pre-use inspection procedures.

Home-care providers should ensure patients and caregivers understand how to identify leakage and when to discontinue therapy.

Given the potential for hypoxia, hypoventilation, and reduced medication delivery, organizations should treat this issue as a high-priority respiratory therapy safety concern until corrective actions are fully implemented.

Links

Read the FDA’s announcement here.

Medical Device Recalls

Pharmacal Recalls MG217 Eczema Cream

Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...

Editorial: Two Days Later, Another Moringa Recall

Recurring Moringa Recalls Highlight Ongoing Supply Chain Concerns On July 17, the U.S. Food and Drug Administration officially closed its investigation into a multistate Salmonella outbreak linked to MOGO-brand moringa capsules. The outbreak was not insignificant....

Moringa Capsules Recalled for Potential Salmonella Contamination

Zen Principle Recalls Moringa Capsules After FDA Detects Salmonella in Raw Ingredient Relay Peak Research LLC, doing business as Zen Principle Naturals, has voluntarily recalled one lot of its Zen Principle® Moringa Capsules after learning that the raw moringa leaf...

Eight Months of Moringa Salmonella Outbreaks

Recurring Salmonella Outbreaks Raise Questions About Supplement Oversight Since November 2025, the U.S. Food and Drug Administration has investigated and coordinated multiple recalls involving moringa dietary supplements contaminated with Salmonella. What initially...

FDA Closes Moringa Salmonella Outbreak Investigation

The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...